Press release

Cilcare strengthens its therapeutic pipeline with two new exclusive licensing agreements with Sanofi

CIL005 and CIL006 extend Cilcare's pipeline to new mechanisms of hearing loss and new patient populations

Montpellier, France – November 16, 2026 – Cilcare, a biotechnology company pioneering auditory science, today announced exclusive licensing agreements with Sanofi for two therapeutic assets, CIL005 and CIL006. The programs expand Cilcare's proprietary pipeline beyond cochlear synaptopathy, the focus of its lead candidate CIL001.

Two programs targeting complementary mechanisms

As in any other organ, the inner ear relies on many cell types, each of which can be damaged through distinct biological mechanisms that define different disorders and patient populations. CIL005 and CIL006 expand Cilcare's pipeline into two complementary areas of hearing biology. **CIL005 targets cochlear inflammation**, a key driver of hearing damage caused by noise, ototoxic treatments, infection or autoimmune conditions. **CIL006 targets oxidative stress**, with an initial focus on a rare hearing disorder.

Cilcare will advance both programs through preclinical proof of concept, using its proprietary disease models and translational expertise in hearing sciences.

The financial terms have not been disclosed.

"Our strategy is to build a differentiated pipeline that reflects the biological diversity of hearing disorders and addresses significant unmet medical needs. CIL005 and CIL006 broaden the scope of our portfolio, allowing us to target distinct disease mechanisms and expand into patient populations with limited therapeutic options," said Patricia Machado, Early Drug Development and Pipeline Director at Cilcare.

"These programs strengthen and diversify our pipeline, and further validate our ability to identify and advance promising opportunities in hearing health. They also reflect our continued partnership with Sanofi, our minority shareholder", said Célia Belline, Chief Executive Officer of Cilcare.

About

***CILCARE*:** Cilcare is a biopharmaceutical company pioneering auditory science, developing drugs and diagnostic tools to prevent and treat hearing disorders. Building on its expertise in auditory neuroscience, Cilcare develops its own pipeline while supporting industrial and academic partners worldwide in their preclinical and clinical programs. Headquartered in Montpellier, France, Cilcare operates in Europe, North America and Asia.

For more information, visit www.cilcare.com

Contacts

CILCARE: Marie PEYTAVY, Marketing & Communication Director /
marie.peytavy@cilcare.com / 07 69 74 19 05